Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer

Oncology Reports

Volumn 12, Issue 4, 2004, Pages 717-723

  Lin, Torng Sen ^a   Chiou, Shiow Her ^b   Wang, Liang Shun ^e   Huang, Hsuan Hua ^g   Chiang, Shu Fen ^b   Shih, Alex Y H ^f   Chen, Y A Lin ^f   Chen, Chih Y I ^c   Hsu, Chung Ping ^c   Hsu, Nan Yung ^d   Chou, Ming Chih ^a   Kuo, Shou Jen ^a   Chow, Kuan Chih ^b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f Taiwan Genome Sciences ^*  (Taiwan)

^g FENG YUAN HOSPITAL   (Taiwan)

Author keywords

Immunohistochemistry; Microarray; Prognosis; RT PCR; Suppression subtractive hybridization

Indexed keywords

COMPLEMENTARY DNA; MATRIX METALLOPROTEINASE; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMAGE SUBTRACTION; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; METASTASIS; MICROARRAY ANALYSIS; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SUBTRACTION TECHNIQUE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 16644397431     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.4.717     Document Type: Article

References (40)

1. Annual reports of the Department of Health, the Executive Yuan, Republic of China, 2000.
2. Schiller JH, Harrington D, Belani CP, et al: The Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
3. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE and Payne WS: Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 38: 331-336, 1984.
4. Hsu NY, Ho HC, Chow KC, et al: Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 61: 2727-2731, 2001.
5. Suzuki T, Fujii Y, Miyano M, Chen LY, Takahashi T and Watanabe K: cDNA cloning, expression, and mutagenesis study of liver-type prostaglandin F synthase. J Biol Chem 274: 241-248, 1999. (Pubitemid 29035055)
6. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
7. Yu Q and Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176,2000. (Pubitemid 30070982)
8. Yu WH, Woessner JF Jr, McNeish JD and Stamenkovic I: CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16: 307-323, 2002. (Pubitemid 34111411)
9. Sternlicht MD and Werb Z: How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 17: 463-516, 2001. (Pubitemid 33096184)
10. Iozzo RV: The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32: 141-174, 1997.
11. Weber IT, Harrison RW and Iozzo RV: Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 271: 31767-31770, 1996. (Pubitemid 26422189)
12. Csordas G, Santra M, Reed CC, et al: Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. I Biol Chem 275: 32879-32887, 2000.
13. Santra M, Eichstetter I and Iozzo RV: An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275: 35153-35161, 2000.
14. Hsieh CC, Chow KC, Fahn HJ, et al: Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 66: 1159-1163, 1998.
15. Yamaguchi Y, Mann DM and Ruoslahti E: Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346: 281-284, 1990.
16. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G and Gress TM: TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93: 204-211, 2001. (Pubitemid 32574276)
17. Yu Q and Stamenkovic I: Cell surface-localized matrix metallo-proteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176, 2000. (Pubitemid 30070982)
18. Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001. (Pubitemid 32952643)
19. Sienel W, Hellers J, Morresi-Hauf A, et al: Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103: 647-651, 2003. (Pubitemid 36091469)
20. Shou Y, Hirano T, Gong Y, et al: Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small cell lung cancer. Br J Cancer 85: 1706-1712, 2001. (Pubitemid 34081517)
21. Diatchenko L, Lau YF, Campbell AP, et al: Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 93: 6025-6030, 1996. (Pubitemid 26190796)
22. Maeda S, Otsuka M, Hirata Y, et al: cDNA microarray analysis of helicobacter pylori - mediated alteration of gene expression in gastric cancer cells. Biochem Biophys Res Commun 284: 443-449, 2001. (Pubitemid 32917996)
23. Yang GP, Ross DT, Kuang WW, Brown PO and Weigel RJ: Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Res 27: 1517-1523, 1999. (Pubitemid 29206295)
24. Tsai CM, Chang KT, Chen JY, Chen YM, Chen MH and Perng RP: Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of pl85neu. Cancer Res 56: 794-801, 1996.
25. Rozen S and Skaletsky HJ: Primer3 on the WWW for general users and for biologist programmers. In: Bioinformatics Methods and Protocols: Methods in Molecular Biology. Krawetz S and Misener S (eds). Humana Press, Totowa, NJ, pp365-386, 2000.
26. Chiou CF, Chow KC, Lin FM, Lin CK, Liu SM and Chen KY: Expression of DNA topoisomerase Ha and multidrug resistance P-glycoprotein in acute leukemia - an immunohistochemical study. Chin Med J 60: 184-190, 1997.
27. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
28. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
29. Knauper V, Will H, Lopez-Otin C, et al: Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 271: 17124-17131, 1996. (Pubitemid 26244262)
30. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A and Vlodavsky I: Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 93: 7069-7074, 1996. (Pubitemid 26243503)
31. Vecchi M, Rudolph-Owen LA, Brown CL, Dempsey PJ and Carpenter G: Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J Biol Chem 273: 20589-20595, 1998. (Pubitemid 28377629)
32. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J and Baselga J: Cleavage of the HER2 ectodomain is a pervanadateactivable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59: 1196-1201, 1999. (Pubitemid 29136246)
33. Nath D, Williamson NJ, Jarvis R and Murphy G: Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 114: 1213-1220, 2001.
34. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR and Landreneau RJ: Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 57: 433-439, 1997. (Pubitemid 27081660)
35. Tsai CM, Perng RP, Chen MH, et al: Greater enhancement of chemosensitivity by caffeine in high p185neu expression human non-small cell lung cancer cell lines. J Natl Cancer Inst 86: 1018-1020, 1994.
36. Brognard J, Clark AS and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001. (Pubitemid 32720961)
37. Brognard J and Dennis PA: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 9: 893-904, 2002. (Pubitemid 35023605)
38. Hammond DE, Carter S, McCullough J, Urbe S, vande Woude G and Clague MJ: Endosomal dynamics of Met determine signaling output. Mol Biol Cell 14: 1346-1354, 2003. (Pubitemid 36547405)
39. Wang LS, Chow KC, Li WY, Liu CC, Wu YC and Huang MH: Clinical significance of serum soluble interleukin-2 receptoralpha in esophageal squamous cell carcinoma. Clin Cancer Res 6: 1445-1451,2000.
40. Chow KC, Chiou SH, Ho SP, et al: The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. Oncol Rep 10: 813-819,2003.